Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Original) (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form.

2. (Original) The substantially crystalline form as claimed in claim 1 in the form of needle-shaped crystals.

3. (Original) The substantially crystalline form as claimed in claim 1 in the form of lath-shaped crystals.

4. (Original) The substantially crystalline form as claimed in claim 1 in the form of a mixture of needle-shaped and lath-shaped crystals.

5. (Currently amended) The substantially crystalline form as claimed in ~~any one of~~ claim ~~s~~ 1 ~~-4-~~ wherein the melting point is greater than 160°C.

6. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees.

7. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern

comprises 2 theta angles at one or more positions selected from the group consisting of 9.21 ±0.05, 13.79 ±0.05, 16.11 ±0.05, 18.11±0.05, and 18.39 ±0.05 degrees.

8. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1 ±0.1, 16.0 ±0.1, 18.0 ±0.1, and 18.3 ±0.1 degrees.

9. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction data are as shown in Table 2.

10. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction data are as shown in Table 4.

11. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction pattern is as shown in Figure 1.

12. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction pattern is as shown in Figure 2.

13. (Currently amended) A method for the preparation of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form ~~as claimed in any one of claims 1 to 12,~~ which method comprises crystallisation of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide from an organic solution, optionally in the presence of water.

14. (Original) A method as claimed in claim 13 wherein the organic solution selected from: an aromatic hydrocarbon, a cycloalkane, an ester, an alcohol or a ketone, or a mixture thereof.

15. Cancelled.

16. (Currently amended) A pharmaceutical composition comprising (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form ~~as claimed in any of claims 1 to 12~~ together with a pharmaceutical carrier and/or excipient.

17. Cancelled.

18. (Currently amended) A method of treating a patient suffering from a condition susceptible to amelioration by a Factor Xa inhibitor comprising administering a therapeutically effective amount of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form ~~as claimed in any of claims 1 to 12~~.